GR113808, a Serotonin Receptor 4 Antagonist, Prevents High-fat-diet-induced Obesity, Fatty Liver Formation, and Insulin Resistance in C57BL/6J Mice

Overview

Journal BMC Pharmacol Toxicol

Publisher Biomed Central

Specialty Pharmacology

Date 2024 Oct 11

PMID 39394150

Authors

Min Hee Kim

Su-Jeong Kim

Woo-Jae Park

Dae Ho Lee

Kyoung-Kon Kim

Affiliations

Soon will be listed here.

Abstract

Background: The burden of nonalcoholic fatty liver disease is increasing, and limited therapeutic drugs are available for its treatment. Serotonin binds to approximately 14 serotonin receptors (HTR) and plays diverse roles in obesity and metabolic complications. In this study, we focused on the function of HTR4 on nonalcoholic fatty liver disease using GR113808, a selective HTR4 antagonist.

Methods: Male C57BL/6J mice were fed high-fat diet for 12 weeks with intraperitoneal GR113808 injection, and HTR expression, weight changes, glucose and lipid metabolism, hepatic fat accumulation, changes in adipose tissue, the changes in transcriptional factors of signaling pathways, and inflammations were assessed. Hep3B cells and 3T3-L1 cells were treated with siRNA targeting HTR4 to downregulate its expression and then cultured with palmitate to mimic a high-fat diet. The changes in transcriptional factors of signaling pathways, and inflammations were assessed in those cells.

Results: After feeding a high-fat diet to male C57BL/6J mice, HTR4 expression in the liver and adipose tissues decreased. GR113808 suppressed body weight gain and improved glucose intolerance. Furthermore, GR113808 not only decreased fatty liver formation but also reduced adipose tissue size. Additionally, GR113808 reduced inflammatory cytokine serum levels and inflammasome complex formation in both tissues. Palmitate treatment in HTR4-downregulated Hep3B cells, also reduced peroxisome proliferator-activated receptor γ and sterol regulatory element-binding protein-1 pathway induction as well as inflammasome complex formation, thus decreasing inflammatory cytokine levels. HTR4 downregulation in 3T3-L1 cells also reduced palmitate-induced inflammasome complex formation and inflammatory cytokine production. Palmitate-induced insulin resistance in Hep3B cells, but not in 3T3-L1 cells, was improved by HTR4 downregulation.

Conclusions: In summary, GR113808 protected against fatty liver formation and improved inflammation in the liver and adipose tissue. Downregulation of HTR4 ameliorated insulin resistance in the liver. These results suggest that HTR4 could serve as a promising therapeutic target for metabolic diseases.

References

. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016; 64(6):1388-402. DOI: 10.1016/j.jhep.2015.11.004. View

Fonseca Pedro P, Tsakmaki A, Bewick G . The Glucose Tolerance Test in Mice. Methods Mol Biol. 2020; 2128:207-216. DOI: 10.1007/978-1-0716-0385-7_14. View

Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K . Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006; 116(7):1784-92. PMC: 1483172. DOI: 10.1172/JCI29126. View

Shimomura I, Bashmakov Y, Horton J . Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem. 1999; 274(42):30028-32. DOI: 10.1074/jbc.274.42.30028. View

Wu S, Wang X, Xing W, Li F, Liang M, Li K . An update on animal models of liver fibrosis. Front Med (Lausanne). 2023; 10:1160053. PMC: 10076546. DOI: 10.3389/fmed.2023.1160053. View

Lee Y, Park J, Lee M, Hardwick J . Hepatic lipid homeostasis by peroxisome proliferator-activated receptor gamma 2. Liver Res. 2019; 2(4):209-215. PMC: 6594548. DOI: 10.1016/j.livres.2018.12.001. View

Wu H, Denna T, Storkersen J, Gerriets V . Beyond a neurotransmitter: The role of serotonin in inflammation and immunity. Pharmacol Res. 2018; 140:100-114. DOI: 10.1016/j.phrs.2018.06.015. View

Powell E, Wong V, Rinella M . Non-alcoholic fatty liver disease. Lancet. 2021; 397(10290):2212-2224. DOI: 10.1016/S0140-6736(20)32511-3. View

Austyn J, Gordon S . F4/80, a monoclonal antibody directed specifically against the mouse macrophage. Eur J Immunol. 1981; 11(10):805-15. DOI: 10.1002/eji.1830111013. View

10.

Kim Y, Lee E, Shin K, Kim M, Pewzner-Jung Y, Lee Y . Hepatic triglyceride accumulation via endoplasmic reticulum stress-induced SREBP-1 activation is regulated by ceramide synthases. Exp Mol Med. 2019; 51(11):1-16. PMC: 6825147. DOI: 10.1038/s12276-019-0340-1. View

11.

Kadowaki T, Hara K, Yamauchi T, Terauchi Y, Tobe K, Nagai R . Molecular mechanism of insulin resistance and obesity. Exp Biol Med (Maywood). 2003; 228(10):1111-7. DOI: 10.1177/153537020322801003. View

12.

Pereira S, Alvarez-Leite J . Low-Grade Inflammation, Obesity, and Diabetes. Curr Obes Rep. 2015; 3(4):422-31. DOI: 10.1007/s13679-014-0124-9. View

13.

Sumida Y, Yoneda M . Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol. 2017; 53(3):362-376. PMC: 5847174. DOI: 10.1007/s00535-017-1415-1. View

14.

El-Merahbi R, Loffler M, Mayer A, Sumara G . The roles of peripheral serotonin in metabolic homeostasis. FEBS Lett. 2015; 589(15):1728-34. DOI: 10.1016/j.febslet.2015.05.054. View

15.

Haub S, Ritze Y, Ladel I, Saum K, Hubert A, Spruss A . Serotonin receptor type 3 antagonists improve obesity-associated fatty liver disease in mice. J Pharmacol Exp Ther. 2011; 339(3):790-8. DOI: 10.1124/jpet.111.181834. View

16.

Lee B, Shao J . Adiponectin and energy homeostasis. Rev Endocr Metab Disord. 2013; 15(2):149-56. PMC: 4006341. DOI: 10.1007/s11154-013-9283-3. View

17.

Fang D, Wan Y, Shen W, Cao J, Sun Z, Yu H . Endoplasmic reticulum stress leads to lipid accumulation through upregulation of SREBP-1c in normal hepatic and hepatoma cells. Mol Cell Biochem. 2013; 381(1-2):127-37. DOI: 10.1007/s11010-013-1694-7. View

18.

Choi W, Namkung J, Hwang I, Kim H, Lim A, Park H . Serotonin signals through a gut-liver axis to regulate hepatic steatosis. Nat Commun. 2018; 9(1):4824. PMC: 6240035. DOI: 10.1038/s41467-018-07287-7. View

19.

Newsome P, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V . A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2020; 384(12):1113-1124. DOI: 10.1056/NEJMoa2028395. View

20.

Pagano C, Soardo G, Esposito W, Fallo F, Basan L, Donnini D . Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol. 2005; 152(1):113-8. DOI: 10.1530/eje.1.01821. View